Nephrectomy was performed in 938 patients with renal carcinoma between the years 1960 and 1986. The cumulative survival rate was 78.7 ± 2.7% after 1 year; 62.9 ± 3.2% after 3 years; 52.4 ± 3.5% after 5 years, and 38.0 ± 4.1% after 10 years. Of this group, 39 patients with lung metastases underwent surgery of their metastases following radical surgical removal of their primary tumor. Using the so-called actuarial method of analysis, the cumulative survival rate of this group was 66.7 ± 15.1 % 1 year after the lung surgery; 47.6 ± 16.3 % after 3 years and 32.7 ± 15.7% after 5 years. The survival rates were correlated with the number of metastases, the operative techniques employed, and with the time interval between primary tumor removal and the appearance of secondary lung metastases. A comparison was made between those patients who underwent curative lung surgery (R0 group) and those with residual tumor (R+ group). Follow-up of the tumor status at the end of the study of the 39 patients is presented.

Keywords:
Renal cell carcinoma, Pulmonary metastases, Survival rates
This content is only available via PDF.
© 1988 S. Karger AG, Basel
1988
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.